SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

旧金山，2024年4月26日/PRNewswire/--Gordian Biotechnology，一家体内药物发现和开发公司，今天宣布了其平台，该平台能够对患者进行预测，体内筛选数百种FDA认可的衰老疾病的基因靶标，规模前所未有。

The company has raised $60 million to date from investors including The Longevity Fund, Arctica Ventures, Athos Service GmbH, Gigafund, Founders Fund, Fifty Years, and former Novartis CEO Thomas Ebeling.

迄今为止，该公司已从包括长寿基金、Arctica Ventures、Athos Service GmbH、Gigafund、Founders Fund、五十年基金和诺华前首席执行官Thomas Ebeling在内的投资者那里筹集了6000万美元。

Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies. The results of these ex vivo studies matched screen predictions with 80% accuracy, and several hits progressed to additional testing and optimization.

戈尔迪安的骨关节炎（OA）项目筛选了数百种自然获得OA的马的疗法，并将数十种疗法推进了人体离体验证研究。这些离体研究的结果与屏幕预测相匹配，准确率为80%，并且几次命中进展为额外的测试和优化。

Gordian presented these findings at the Osteoarthritis Research Society International (OARSI) World Congress last week..

戈尔迪安上周在国际骨关节炎研究学会（OARSI）世界大会上介绍了这些发现。。

In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH). The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists..

在最初开发过程中的概念验证实验中，Gordian将50种基因疗法的合并文库引入代谢相关脂肪性肝炎（MASH）的小鼠模型中。使用该公司专有的体内筛选平台对这些疗法进行了评估，该平台成功地概括了16种临床结果中的13种，用于临床数据存在的目标。。

Today, Gordian is completing in vivo screens of thousands of novel single and multi-target therapies across four indications in highly representative animal models across multiple species.

今天，Gordian正在完成数千种新型单靶和多靶治疗的体内筛选，这些治疗跨越了多个物种的高度代表性动物模型中的四个适应症。

'Gordian leverages recent advancements in single-cell sequencing and gene therapy to discover and predict what drugs will be successful in a way that would have been inconceivable just five years ago,' said co-founder and CEO Francisco LePort. 'Our ultimate goal is to help people wake up every day, more capable than the one before.'.

联合创始人兼首席执行官弗朗西斯科·莱波特（Francisco LePort）说：“戈尔迪安（Gordian）利用单细胞测序和基因治疗的最新进展，发现并预测哪些药物将以五年前难以想象的方式取得成功。”我们的最终目标是帮助人们每天醒来，比以前更有能力。”。

The first and only platform of its kind

第一个也是唯一一个此类平台

Screening in vivo lets Gordian run the equivalent of hundreds of preclinical experiments in a matter of months and at a small fraction of the cost of traditional preclinical studies. Thus, enormous amounts of in vivo data are obtained at the beginning of the discovery process in animal models that would otherwise be impractical to use, allowing only the most efficacious therapeutics to move into development and clinical trials..

体内筛选可以让Gordian在几个月内进行数百次临床前实验，而成本仅为传统临床前研究的一小部分。因此，在动物模型的发现过程开始时获得了大量的体内数据，否则这些数据将不切实际，只有最有效的治疗方法才能进入开发和临床试验。。

The Gordian platform consists of three proprietary components working in concert:

Gordian平台由三个协同工作的专有组件组成：

Patient Avatars™ are animal models with biology more representative of human patients than those typically used, such as horses for OA and monkeys for MASH. Because few animals are required for screening, Gordian can use large or advanced animal models that would otherwise be impractical for extensive preclinical studies.

患者化身™是一种动物模型，其生物学特性比通常使用的动物模型更能代表人类患者，例如用于OA的马和用于MASH的猴子。由于筛查所需的动物很少，Gordian可以使用大型或先进的动物模型，否则对于广泛的临床前研究是不切实际的。

Often these animal models acquire the disease naturally and therefore have other conditions associated with biological aging, as a human would..

这些动物模型通常是自然获得疾病的，因此也有其他与生物衰老相关的疾病，就像人类一样。。

Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar. The diseased tissue becomes a 'mosaic,' where different cells receive different barcoded therapies. The therapies are introduced at a low dose, such that each perturbed cell is separated by diseased tissue unperturbed by any treatment, minimizing interactions between treatments.

Mosaic Screening™是体内筛选的集合，可在单个患病动物（患者化身）中同时测试数百种疗法。患病组织变成“马赛克”，不同的细胞接受不同的条形码治疗。这些疗法以低剂量引入，使得每个受干扰的细胞被不受任何治疗干扰的患病组织分开，从而最小化治疗之间的相互作用。

Each of these cells is sequenced, revealing the effect of each therapy in the full diseased in vivo context..

对这些细胞中的每一个进行测序，揭示每种疗法在体内完全患病的情况下的作用。。

Pythia™ is an analysis methodology that uses artificial intelligence to interpret single-cell data from hundreds of cellular experiments and measure the effect of each therapy in vivo. By analyzing this data alongside existing human pathology data, Gordian determines which therapies are most likely to succeed in preclinical development and clinical trials..

Pythia™是一种分析方法，它使用人工智能来解释来自数百个细胞实验的单细胞数据，并测量每种疗法在体内的效果。通过分析这些数据以及现有的人类病理学数据，Gordian确定了哪些疗法最有可能在临床前开发和临床试验中取得成功。。

'Our most severe unmet medical needs are the result of aging. This is due to the complexities of the aging body, often involving multiple comorbidities at once, making research and development especially challenging and expensive,' said Martin Borch Jensen, Gordian co-founder and chief scientific officer.

“我们最严重的未满足医疗需求是老龄化的结果。Gordian联合创始人兼首席科学官马丁·博奇·延森（MartinBorchJensen）说，这是由于衰老身体的复杂性，通常同时涉及多种合并症，使得研究和开发尤其具有挑战性和昂贵。

'Gordian is creating a future in which age-related ailments are treated and cured as effectively as infectious diseases today.'.

“戈尔迪安正在创造一个与年龄有关的疾病得到治疗和治愈的未来，就像今天的传染病一样有效。”。

Aging is the ultimate risk factor for humans, the most expensive, yet research is under-funded.

衰老是人类的最终风险因素，是最昂贵的，但研究资金不足。

'Age-related diseases are incredibly complex, and a living animal, ideally one that is aged and acquired the disease naturally, is the only experimental system that can capture this complexity,' said Laura Deming, a partner at The Longevity Fund and Gordian investor. 'Our ability to understand these diseases is bottlenecked by the rate we can run tests in these living systems.

长寿基金合伙人、戈尔迪安投资者劳拉·戴明（LauraDeming）说，与年龄有关的疾病极其复杂，唯一能够捕捉这种复杂性的实验系统是活的动物，最好是自然衰老并获得这种疾病的动物我们在这些生命系统中进行测试的速度限制了我们理解这些疾病的能力。

Scaling that rate by over 100 fold is really exciting and is a huge leap toward curing age-related disease.'.

将这一比率提高100倍以上确实令人兴奋，这是治疗与年龄有关的疾病的一个巨大飞跃。”。

In addition to MASH and OA, Gordian's current focus indications include heart failure with preserved ejection fraction and pulmonary fibrosis. The platform is capable of discovering therapies for a long list of complex diseases. The company seeks to partner with pharmaceutical companies to develop drugs as well as move therapeutics into the clinic internally..

除了MASH和OA，Gordian目前的重点适应症还包括射血分数保留的心力衰竭和肺纤维化。该平台能够发现一长串复杂疾病的治疗方法。该公司寻求与制药公司合作开发药物，并在内部将治疗药物转移到诊所。。

LePort and Borch Jensen studied and worked in separate scientific fields in different parts of the world before meeting in early 2018 as a result of their shared interest in longevity entrepreneurship. They founded Gordian in October of that year.

由于对长寿创业的共同兴趣，LePort和Borch Jensen在2018年初会面之前，曾在世界不同地区的不同科学领域学习和工作。他们在那年10月成立了戈尔迪安。

About Gordian Biotechnology

关于Gordian Biotechnology

Founded in 2018 and headquartered in San Francisco, Gordian is an in vivo drug discovery and development company whose mission is to cure age-related diseases. Named for solving intractable problems by changing the rules, the company has developed an innovative in vivo screening platform that tests thousands of gene therapies and predicts clinical outcomes with unprecedented accuracy and efficiency.

Gordian成立于2018年，总部位于旧金山，是一家体内药物发现和开发公司，其使命是治疗与年龄有关的疾病。该公司以通过改变规则来解决棘手问题而命名，它开发了一种创新的体内筛选平台，可以测试数千种基因疗法，并以前所未有的准确性和效率预测临床结果。

The Gordian Platform comprises three proprietary components working in concert to drive predictive ability. Mosaic Screening is the Gordian method of pooled in vivo screening, Patient Avatars are animals most representative of humans, and Pythia is an analysis methodology that combines Gordian screening data with existing human data and uses machine learning to maximize predictive power.

Gordian平台由三个专有组件组成，协同工作以提高预测能力。马赛克筛选是Gordian的体内筛选方法，患者化身是最能代表人类的动物，Pythia是一种分析方法，它将Gordian筛选数据与现有人类数据相结合，并使用机器学习来最大程度地提高预测能力。

The company is funded by world-renowned investors including The Longevity Fund, Athos Service GmbH, Gigafund, Founders Fund, and former Novartis CEO Thomas Ebeling. Gordian: Creating Time..

该公司由世界知名投资者资助，包括长寿基金、Athos Service GmbH、Gigafund、Founders Fund和诺华前首席执行官Thomas Ebeling。戈尔迪安：创造时间。。